Figure 1
Flow chart for selection of studies.
Table 1
Baseline characteristics of trials included in meta-analysis.
| STUDY(REF. #) | YEAR | QUALITY SCORE | FOLLOW-UP WEEKS | PH TYPE | REGIMEN | n | AGE, YEARS (SD) | MALE, % | 6MWD, M (SD) | WHO FC, % | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | II | III | IV | ||||||||||
| Gatzoulis (15) | 2019 | 19 | 16 | PAH | Macitentan | 114 | 33 * | 28.1 | 368.7 (74.5) | 0 | 60.5 | 30.5 | 0 |
| Placebo | 112 | 31 * | 39.3 | 380.3 (76.3) | 0 | 58.9 | 41.1 | 0 | |||||
| Ghofrani (16) | 2017 | 20 | 24 | CTEPH | Macitentan | 40 | 58.2 (14.0) | 35 | 353.0 (87.9) | 0 | 30 | 70 | 0 |
| Placebo | 40 | 56.9 (13.9) | 38 | 351.2 (73.8) | 0 | 15 | 82.5 | 2.5 | |||||
| Pulido (17) | 2013 | 18 | 104 | PAH | Macitentan | 242 | 44.5 (16.3) | 19.8 | 363 (93.2) | 0.4 | 49.6 | 47.9 | 2.1 |
| Placebo | 250 | 46.7 (17.0) | 26.1 | 352 (110.6) | 0 | 51.8 | 46.6 | 1.6 | |||||
| Sitbon (19) | 2019 | 21 | 12 | PAH | Macitentan | 43 | 58.0 (8.7) | 51 | 385.8 (100.0) | 2 | 63 | 35 | 0 |
| Placebo | 42 | 59.0 (9.5) | 52 | 383.2 (108.9) | 2 | 55 | 43 | 0 | |||||
| Vachiéry (20) | 2018 | 17 | 12 | PH-LHD | Macitentan | 31 | 70.0 * | 19.4 | 300 * | 0 | 16.1 | 83.9 | 0 |
| Placebo | 32 | 72.0 * | 50.0 | 305 * | 0 | 31.3 | 68.8 | 0 | |||||
| SOPRANO (28) | 2021 | 16 | 12 | PH-LHD | Macitentan | 28 | 56.5 (8.2) | 78.6 | NR | NR | NR | NR | NR |
| Placebo | 29 | 58.2 (7.0) | 79.3 | NR | NR | NR | NR | NR | |||||
[i] Abbreviations: CTEPH, chronic thromboembolic pulmonary hypertension; 6MWD, 6-min walk distance; NR, not reported; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PH-LHD, PH secondary to left heart disease; SD, standard deviation; WHO FC, World Health Organization functional class. * Median.
Figure 2
Forest plot assessing the efficacy of macitentan on (A) 6-min walk distance, (B) pulmonary vascular resistance, (C) mean pulmonary artery pressure, (D) NT-proBNP, and (E) cardiac index.
Figure 3
Forest plot assessing the efficacy of macitentan on (A) improvement in WHO FC, (B) hospitalization for worsening of PH, (C) PH-related death, and (D) all-cause death.